SRS Capital Advisors Inc. Has $435,000 Stock Holdings in Abbott Laboratories (NYSE:ABT)

SRS Capital Advisors Inc. lessened its holdings in Abbott Laboratories (NYSE:ABT) by 9.2% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 3,948 shares of the healthcare product maker’s stock after selling 400 shares during the period. SRS Capital Advisors Inc.’s holdings in Abbott Laboratories were worth $435,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also recently made changes to their positions in the stock. Los Angeles Capital Management LLC boosted its position in Abbott Laboratories by 2.8% during the 4th quarter. Los Angeles Capital Management LLC now owns 291,047 shares of the healthcare product maker’s stock worth $32,036,000 after buying an additional 7,837 shares during the period. Natixis Advisors L.P. lifted its position in shares of Abbott Laboratories by 37.5% during the fourth quarter. Natixis Advisors L.P. now owns 965,930 shares of the healthcare product maker’s stock valued at $106,320,000 after purchasing an additional 263,186 shares in the last quarter. Benjamin Edwards Inc. boosted its stake in shares of Abbott Laboratories by 3.8% in the 4th quarter. Benjamin Edwards Inc. now owns 50,889 shares of the healthcare product maker’s stock worth $5,601,000 after buying an additional 1,856 shares during the last quarter. Commonwealth Equity Services LLC increased its position in shares of Abbott Laboratories by 1.8% during the 4th quarter. Commonwealth Equity Services LLC now owns 880,721 shares of the healthcare product maker’s stock valued at $96,941,000 after purchasing an additional 15,609 shares during the last quarter. Finally, Summit Asset Management LLC boosted its stake in Abbott Laboratories by 6.9% in the fourth quarter. Summit Asset Management LLC now owns 3,919 shares of the healthcare product maker’s stock valued at $431,000 after acquiring an additional 252 shares during the last quarter. Institutional investors own 75.18% of the company’s stock.

Abbott Laboratories Stock Down 0.0 %

ABT stock traded down $0.04 on Friday, reaching $105.88. 3,610,292 shares of the company traded hands, compared to its average volume of 5,562,046. The company has a debt-to-equity ratio of 0.35, a current ratio of 1.64 and a quick ratio of 1.16. The firm has a fifty day simple moving average of $112.79 and a 200-day simple moving average of $108.41. Abbott Laboratories has a one year low of $89.67 and a one year high of $121.64. The company has a market cap of $183.72 billion, a P/E ratio of 32.98, a price-to-earnings-growth ratio of 2.56 and a beta of 0.76.

Abbott Laboratories (NYSE:ABT) last posted its earnings results on Wednesday, April 17th. The healthcare product maker reported $0.98 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.96 by $0.02. The business had revenue of $9.96 billion for the quarter, compared to analysts’ expectations of $9.88 billion. Abbott Laboratories had a net margin of 13.96% and a return on equity of 20.32%. The business’s revenue for the quarter was up 2.2% compared to the same quarter last year. During the same quarter in the prior year, the business earned $1.03 EPS. Research analysts anticipate that Abbott Laboratories will post 4.62 earnings per share for the current year.

Abbott Laboratories Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Wednesday, May 15th. Stockholders of record on Monday, April 15th will be issued a $0.55 dividend. This represents a $2.20 annualized dividend and a dividend yield of 2.08%. The ex-dividend date of this dividend is Friday, April 12th. Abbott Laboratories’s dividend payout ratio (DPR) is presently 68.54%.

Insider Buying and Selling

In other Abbott Laboratories news, VP John A. Jr. Mccoy sold 472 shares of the stock in a transaction on Friday, March 1st. The shares were sold at an average price of $118.50, for a total transaction of $55,932.00. Following the completion of the transaction, the vice president now owns 18,760 shares in the company, valued at $2,223,060. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. In other news, EVP Daniel Gesua Sive Salvadori sold 963 shares of the company’s stock in a transaction that occurred on Friday, March 1st. The stock was sold at an average price of $118.50, for a total transaction of $114,115.50. Following the transaction, the executive vice president now owns 125,697 shares of the company’s stock, valued at $14,895,094.50. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, VP John A. Jr. Mccoy sold 472 shares of the company’s stock in a transaction dated Friday, March 1st. The stock was sold at an average price of $118.50, for a total transaction of $55,932.00. Following the completion of the transaction, the vice president now owns 18,760 shares in the company, valued at $2,223,060. The disclosure for this sale can be found here. Over the last three months, insiders have sold 13,935 shares of company stock worth $1,670,048. Corporate insiders own 1.10% of the company’s stock.

Analysts Set New Price Targets

Several research analysts have recently weighed in on the company. Raymond James reiterated a “buy” rating and set a $124.00 price target on shares of Abbott Laboratories in a research note on Wednesday, April 24th. Barclays dropped their target price on Abbott Laboratories from $141.00 to $140.00 and set an “overweight” rating on the stock in a research report on Monday, April 22nd. Royal Bank of Canada reduced their price objective on shares of Abbott Laboratories from $128.00 to $125.00 and set an “outperform” rating for the company in a research note on Thursday, April 18th. Citigroup increased their price objective on Abbott Laboratories from $126.00 to $128.00 and gave the stock a “buy” rating in a research report on Wednesday, April 3rd. Finally, Evercore ISI lifted their price target on Abbott Laboratories from $120.00 to $125.00 and gave the company an “outperform” rating in a research report on Thursday, April 4th. Three research analysts have rated the stock with a hold rating and seven have given a buy rating to the stock. According to data from MarketBeat.com, Abbott Laboratories currently has an average rating of “Moderate Buy” and an average price target of $121.50.

About Abbott Laboratories

Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon.